• Aucun résultat trouvé

AbbVie Makes SEC Filings Relating To Its Previously Announced Agreement and Plan of Reorganization with Pharmacyclics, Inc.

N/A
N/A
Info
Télécharger
Protected

Academic year: 2022

Partager "AbbVie Makes SEC Filings Relating To Its Previously Announced Agreement and Plan of Reorganization with Pharmacyclics, Inc."

Copied!
1
0
0

Chargement.... (Voir le texte intégral maintenant)

Texte intégral

(1)AbbVie Makes SEC Filings Relating To Its Previously Announced Agreement and Plan of Reorganization with Pharmacyclics, Inc. NORTH CHICAGO, ILLINOIS, U.S.A., May 26, 2015 – AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has filed an amendment to its tender offer statement on Schedule TO and a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (“SEC”) relating to its previously announced agreement and plan of reorganization with Pharmacyclics, Inc. AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after AbbVie electronically files these documents with, or furnishes them to, the SEC. These documents are posted on AbbVie’s website at www.abbvieinvestor.com. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC’s home page at http://www.sec.gov. Copies of the above referenced information will also be made available, free of charge, upon written request to AbbVie Inc., Investor Relations, 1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A. SOURCE: AbbVie Inc.. WorldReginfo - 0f4b9cc9-b89c-494e-8ce4-c9e8aab0da99. CONTACT: AbbVie Inc., 1-847-938-8745.

(2)

Références

Télécharger maintenant ( PDF - 1 Page - 47.26 KB )

Documents relatifs

AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.

Important Additional Information This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, shares of common stock of Pharmacyclics, nor is it

AbbVie Files Documentation with the Securities and Exchange Commission In Connection With a Registered Debt Offering

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section

AbbVie Files a Current Report on Form 8-K

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section

AbbVie Files Form 8-K

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section

annual report on form 10

Many other factors can affect AbbVie’s profitability and financial condition, including: • changes in or interpretations of laws and regulations, including changes in

AbbVie Reports Third-Quarter 2014 Financial Results

As reported GAAP Adjusted for specified items: Intangible asset amortization Separation costs R&D Acquired IPR&D Calico collaboration Shire transaction costs Other As

Document Number: 1233402 Version: 3

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section

Document Number: 1233402 Version: 3

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section